Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billionMarket Watch • 12/28/20
Why This Recently Approved Prostate Cancer Treatment Could Be Huge for Myovant24/7 Wall Street • 12/28/20
UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women's HealthGlobeNewsWire • 12/28/20
Myovant shares soar 16% premarket on news of Pfizer cancer drug deal worth up to $4.2 billionMarket Watch • 12/28/20
Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women's HealthGlobeNewsWire • 12/28/20
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's HealthGlobeNewsWire • 12/28/20
Moderna or Pfizer? Which Company Stands to Gain the Most From Vaccine RolloutThe Motley Fool • 12/27/20
Pfizer's Pipeline Candidate That Could Be a Bigger Winner Than Its COVID VaccineThe Motley Fool • 12/26/20
Vaccine Stocks Rebound On Pfizer's U.S. Deal, Moderna OK In CanadaInvestors Business Daily • 12/23/20
Pfizer and BioNTech to Supply Feds With 100 Million Additional Doses of Coronavirus VaccineThe Motley Fool • 12/23/20
Pfizer to deliver 100 million additional doses of its COVID-19 vaccine to the U.S. governmentInvezz • 12/23/20